Literature DB >> 25636208

Analysis of global gene expression profiles suggests a role of acute inflammation in type 3C diabetes mellitus caused by pancreatic ductal adenocarcinoma.

Wenchao Gao1, Yu Zhou, Qingyan Li, Quanbo Zhou, Langping Tan, Yadong Song, Xiaohui Zhao, Min Yu, Shangyou Zheng, Huilin Ye, Bing Zeng, Qing Lin, Jiajia Zhou, Yimin Liu, Huaiqiu Huang, Hui Zhang, Xuchu Hu, Zhihua Li, Xianhua Dai, Rufu Chen.   

Abstract

AIMS/HYPOTHESIS: Pancreatic ductal adenocarcinoma (PDAC) can cause type 3C diabetes, known as PDAC-associated diabetes mellitus (PDAC-DM), but the mechanism is unknown. This study aimed to reveal the mechanism.
METHODS: PDAC lesions from patients with or without PDAC-DM (n = 4 in each group) were individually profiled for 23,512 mRNAs with microarrays. Bioinformatic analysis and in vivo and in vitro assays were then conducted.
RESULTS: We determined that 2,778 genes were differentially expressed; over-representation of ten genes was validated with quantitative RT-PCR. The analysis of gene ontology showed that the differentially expressed secretory genes were related mainly to inflammation. High levels of a marker of inflammation (C-reactive protein [CRP]) and an inflammatory mediator (TNF super-family member 13 [TNFSF13]) were found in the serum of patients with PDAC-DM. After surgical resection of PDAC lesions, CRP and TNFSF13 levels significantly decreased (p < 0.01). Furthermore, we found that the levels of TNFSF13 in PDAC lesions and TNFSF13 and CRP in serum were significantly correlated with the diabetic status of patients with PDAC-DM (p < 0.01). Assays in vivo showed that after exposure to an inhibitor of inflammation (celecoxib), the fasting blood glucose level in the mouse model of PDAC-DM dramatically decreased from 6.9 ± 0.1 to 5.6 ± 0.1 mmol/l in 2-4 days (p < 0.01). CONCLUSIONS/
INTERPRETATION: We found that acute inflammation was involved in the pathogenesis of PDAC-DM. We contend that acute inflammation is a potential target for the diagnosis and treatment of PDAC-DM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25636208     DOI: 10.1007/s00125-014-3481-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  24 in total

1.  Glucose metabolic alterations in isolated and perfused rat hepatocytes induced by pancreatic cancer conditioned medium: a low molecular weight factor possibly involved.

Authors:  A Valerio; D Basso; L Brigato; G Ceolotto; G Baldo; A Tiengo; M Plebani
Journal:  Biochem Biophys Res Commun       Date:  1999-04-13       Impact factor: 3.575

Review 2.  Cyclooxygenase-2: a therapeutic target.

Authors:  Marco E Turini; Raymond N DuBois
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

Review 3.  Inflammatory mediators involved in the progression of the metabolic syndrome.

Authors:  Kuifen Ma; Xi Jin; Xingguang Liang; Qingwei Zhao; Xingguo Zhang
Journal:  Diabetes Metab Res Rev       Date:  2012-03-02       Impact factor: 4.876

Review 4.  Mechanisms of disease:Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes.

Authors:  Deborah M Muoio; Christopher B Newgard
Journal:  Nat Rev Mol Cell Biol       Date:  2008-03       Impact factor: 94.444

Review 5.  Targeting inflammation in the treatment of type 2 diabetes: time to start.

Authors:  Marc Y Donath
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

6.  Serum APRIL, a potential tumor marker in pancreatic cancer.

Authors:  Feng Wang; Lin Chen; Weifeng Ding; Guihua Wang; Yueping Wu; Jingchun Wang; Leilei Luo; Hui Cong; Yueguo Wang; Shaoqing Ju; Jianguo Shao; Huimin Wang
Journal:  Clin Chem Lab Med       Date:  2011-05-25       Impact factor: 3.694

Review 7.  Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin.

Authors:  M K Piya; P G McTernan; S Kumar
Journal:  J Endocrinol       Date:  2013-01-02       Impact factor: 4.286

Review 8.  Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease?

Authors:  Nils Ewald; Reinhard G Bretzel
Journal:  Eur J Intern Med       Date:  2013-02-01       Impact factor: 4.487

9.  Identification of proteins implicated in the development of pancreatic cancer-associated diabetes mellitus by iTRAQ-based quantitative proteomics.

Authors:  Wan-Sheng Wang; Xiao-Hui Liu; Ling-Xiao Liu; Da-Yong Jin; Peng-Yuan Yang; Xiao-Lin Wang
Journal:  J Proteomics       Date:  2013-04-06       Impact factor: 4.044

10.  Attenuated EAN in TNF-α deficient mice is associated with an altered balance of M1/M2 macrophages.

Authors:  Hong-Liang Zhang; Mohammed Y Hassan; Xiang-Yu Zheng; Sheikh Azimullah; Hernan Concha Quezada; Naheed Amir; Mohamed Elwasila; Eilhard Mix; Abdu Adem; Jie Zhu
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

View more
  3 in total

Review 1.  The Impact of Pancreatic Exocrine Diseases on the β-Cell and Glucose Metabolism-A Review with Currently Available Evidence.

Authors:  Marina Ciochina; Daniel Vasile Balaban; George Manucu; Mariana Jinga; Cristian Gheorghe
Journal:  Biomolecules       Date:  2022-04-21

2.  Integrating Genome-Wide Association and eQTLs Studies Identifies the Genes and Gene Sets Associated with Diabetes.

Authors:  Xiao Liang; Awen He; Wenyu Wang; Li Liu; Yanan Du; Qianrui Fan; Ping Li; Yan Wen; Jingcan Hao; Xiong Guo; Feng Zhang
Journal:  Biomed Res Int       Date:  2017-06-28       Impact factor: 3.411

3.  Identification of Key Genes Involved in Pancreatic Ductal Adenocarcinoma with Diabetes Mellitus Based on Gene Expression Profiling Analysis.

Authors:  Weiyu Zhou; Yujing Wang; Hongmei Gao; Ying Jia; Yuanxin Xu; Xiaojing Wan; Zhiying Zhang; Haiqiao Yu; Shuang Yan
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.